Live Analyst Rating Changes 21785 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Robert Driscoll
WEDB

Robert Driscoll

Wedbush
Wall Street Analyst
★★★★☆
#418
on 13Foresight · ranked by our own returns
63%
Success Rate
+12.5%
Average Return
33 of 52 calls profitable · +8.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of Robert Driscoll's ratings turned a profit when each position was held for 1 year — averaging +12.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

111 Buy 10 Hold 3 Sell
Robert's Stock Coverage 31 ratings · 2026-08-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
REPL
Replimune Group
 Aug 07, 2026 BUY Strong Buy
+80.0% avg upside
14 analysts
$19.00
57.50% Upside
 · ·
RCUS
Arcus Biosciences
 Aug 06, 2026 BUY Strong Buy
+24.4% avg upside
20 analysts
$43.00
50.32% Upside
 +0.0% ·
RVMD
Revolution Medicines
 Aug 06, 2026 BUY Strong Buy
-19.3% avg upside
32 analysts
$201.00
2.05% Downside
 +3.1% ·
BDTX
Black Diamond Therapeutics
 Aug 06, 2026 BUY Strong Buy
+628.6% avg upside
12 analysts
$14.00
618.01% Upside
 +1.6% ·
ARVN
Arvinas Holding Company
 Aug 05, 2026 HOLD Buy
+226.7% avg upside
28 analysts
$12.00
37.09% Upside
 +6.6% ·
TYRA
Tyra Bioscience
 Aug 05, 2026 BUY Strong Buy
+69.3% avg upside
17 analysts
$53.00
99.94% Upside
 +3.1% ·
IDYA
IDEAYA Biosciences
 Aug 05, 2026 BUY Strong Buy
+31.2% avg upside
29 analysts
$60.00
62.05% Upside
 +0.5% ·
GLUE
Monte Rosa Therapeutics
 Aug 03, 2026 BUY Strong Buy
+41.9% avg upside
15 analysts
$27.00
70.01% Upside
 +3.2% ·
CBIO
Crescent Biopharma
 Jul 31, 2026 BUY Strong Buy
+31.7% avg upside
17 analysts
$27.00
60.42% Upside
 +16.4% ·
CGEM
Cullinan Management
 Jul 29, 2026 BUY Strong Buy
+91.8% avg upside
15 analysts
$37.00
108.74% Upside
 +3.0% ·
KURA
Kura Oncology
 Jul 28, 2026 BUY Strong Buy
+170.9% avg upside
26 analysts
$36.00
276.09% Upside
 +2.8% ·
FHTX
Foghorn Therapeutics
 Jul 20, 2026 BUY Strong Buy
+92.3% avg upside
17 analysts
$10.00
64.80% Upside
 +7.3% ·
CTMX
CytomX Therapeutics
 Jun 04, 2026 BUY Strong Buy
+216.7% avg upside
21 analysts
$11.00
217.87% Upside
 +8.8% ·
CRBP
Corbus Pharmaceuticals
 May 27, 2026 BUY Strong Buy
+261.2% avg upside
20 analysts
$30.00
195.01% Upside
 +30.0% ·
PYXS
Pyxis Oncology
 May 18, 2026 BUY Strong Buy
+95.0% avg upside
14 analysts
$6.00
60.87% Upside
 +84.7% ·
CGON
CG Oncology, Inc.
 May 18, 2026 BUY Strong Buy
+14.3% avg upside
17 analysts
$80.00
6.43% Upside
 +19.3% ·
ACET
Adicet Bio
 May 14, 2026 BUY Strong Buy
+216.9% avg upside
14 analysts
$25.00
213.23% Upside
 -5.1% ·
TNGX
Tango Therapeutics
 May 14, 2026 BUY Strong Buy
+42.2% avg upside
15 analysts
$33.00
22.00% Upside
 +8.8% ·
APRE
Aprea Therapeutics
 May 14, 2026 BUY Buy
+3295.9% avg upside
7 analysts
$6.00
822.58% Upside
 -30.9% ·
AVTX
Avalo Therapeutics
 May 14, 2026 BUY Strong Buy
+180.6% avg upside
20 analysts
$34.00
85.55% Upside
 +0.5% ·
EIKN
Eikon Therapeutics, Inc.
 May 12, 2026 SELL Buy
+155.7% avg upside
5 analysts
$5.00
46.12% Downside
 +19.4% ·
JANX
Janux Therapeutics Inc
 May 08, 2026 BUY Strong Buy
+191.2% avg upside
21 analysts
$36.00
127.19% Upside
 +12.5% ·
HOWL
Werewolf Therapeutics
 Dec 19, 2025 HOLD Strong Buy
+1633.8% avg upside
8 analysts
$1.00
151.78% Upside
 -41.5% ·
ZNTL
Zentalis Pharmaceuticals
 Aug 07, 2025 HOLD Buy
+233.4% avg upside
18 analysts
$4.00
5.26% Downside
 +226.9% ·
GYRE
Gyre Therapeutics
 Jul 14, 2025 BUY Strong Buy
+211.6% avg upside
15 analysts
$27.00
304.77% Upside
 -16.7% ·
GERN
Geron
 May 08, 2025 BUY Strong Buy
+189.2% avg upside
19 analysts
$6.00
305.39% Upside
 +10.3% ·
CMPX
Compass Therapeutics
 Aug 14, 2024 BUY Strong Buy
+342.8% avg upside
20 analysts
$8.00
272.18% Upside
 +158.8% ·
GILD
Gilead Sciences
 Nov 19, 2021 BUY Strong Buy
-10.8% avg upside
66 analysts
$67.00
49.62% Downside
 +27.5% ·
ABUS
Arbutus Biopharma
 Mar 08, 2021 BUY Strong Buy
+91.6% avg upside
15 analysts
$6.00
29.66% Upside
 -11.1% ·
CRVS
Corvus Pharmaceuticals
 Oct 05, 2020 BUY Strong Buy
+83.7% avg upside
14 analysts
$8.00
42.48% Downside
 -2.9% ·
NBRVF
Nabriva Therapeutics
 Mar 19, 2020 HOLD Strong Buy
+13374900.0% avg upside
9 analysts
$10.00
9999899.92% Upside
 · ·
🔒 26 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Robert Driscoll — Frequently Asked Questions
How accurate are Robert Driscoll's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Robert's ratings were profitable over a one-year hold, with an average return of +12.5% per rating, or +8.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Robert ranked on 13Foresight?
Robert Driscoll is currently ranked #418 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Robert cover?
Robert most recently has ratings on REPL, RCUS, RVMD, BDTX, ARVN, TYRA, IDYA, GLUE, CBIO, CGEM, KURA, FHTX and 19 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.